To assess the effect of chlorambucil compared to other therapeutic regimens on overall survival, progression free survival, and response rates in patients with CLL/SLL requiring therapy. We will include patients receiving chlorambucil as first-line therapy and patients with relapsed or refractory CLL/SLL receiving salvage therapy with chlorambucil.